The global Genetic Modification Therapies market is expected to exceed more than US$ 3.5 Billion by 2024 at a CAGR of 34% in the given forecast period.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Browse Full Report: https://www.marketresearchengine.com/genetic-modification-therapies-market

The global Genetic Modification Therapies market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Genetic Modification Therapies market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Genetic modification therapies, significantly gene therapy and RNA therapy, have existed for many years, with very little clinical success. However, recent enhancements in these therapies, together with higher delivery systems, additional economical and sturdy gene expression constructs, precise polymer editing tools, have brought this industry to the forefront, and its currently poised for explosive growth within the coming back years.

Because of the potentially curative nature of those medicines theres monumental potential in several applications, starting from cancer to neurology to rare diseases. Genetic modification therapies represent consecutive wave of medicines with monumental potential for treating and curing draining and high diseases. As a result of its wide scope, genetic modification therapy can play a vital role within the future world medical economy.

Continuing advances in key technologies like DNA editing, viral design and production, and gene expression, further as a pressing medical want in several serious and enervating disorders, are driving the expansion of the marketplace for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies trade and build distinctive market opportunities.

The overall market is anticipated to witness important growth in opportunities for a spread of stakeholders within the returning decade. its necessary to spotlight that many technology suppliers, reaching to develop and / or support the event of gene therapies, with improved effectiveness and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation during this domain has additionally semiconductor diode to the invention of novel molecular targets and strong the analysis pipelines of corporations targeted during this house. the potential to focus on numerous therapeutic areas is taken into account to be amongst the foremost outstanding growth drivers of this market.

Market Insights

The global Genetic Modification Therapies market is segregated on the basis of Platform Technology as Gene editing, Gene Therapies, Genetically Modified Cell Therapies, and RNA Therapies. Based on Delivery Technologies the global Genetic Modification Therapies market is segmented in AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral, and Nonviral Based on End-User Industry the global Genetic Modification Therapies market is segmented in Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, and Others.

Based on Disease, the global Genetic Modification Therapies market is segmented in Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases, Other Indications.

Competitive Rivalry

4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others are among the major players in the global Genetic Modification Therapies market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Genetic Modification Therapies Market has been segmented as below:

The Genetic Modification Therapies Market is segmented on the lines of Genetic Modification Therapies Market, By Platform Technology, Genetic Modification Therapies Market, By Delivery Technologies, Genetic Modification Therapies Market, By End-User Industry, Genetic Modification Therapies Market, By Disease, Genetic Modification Therapies Market, By Region and Genetic Modification Therapies Market, By Company.

Genetic Modification Therapies Market, By Platform Technology this market is segmented on the basis of Gene editing, Gene Therapies, Genetically Modified Cell Therapies and RNA Therapies. Genetic Modification Therapies Market, By Delivery Technologies this market is segmented on the basis of AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral and Nonviral. Genetic Modification Therapies Market, By End-User Industry this market is segmented on the basis of Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations and Others. Genetic Modification Therapies Market, By Disease this market is segmented on the basis of Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases and Other Indications. Genetic Modification Therapies Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Genetic Modification Therapies Market, By Company this market is segmented on the basis of 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore and Jivana Biotechnology.

The report covers:

Report Scope:

The global Genetic Modification Therapies market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Genetic Modification Therapies market share. Major industry players with significant revenue share include 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/genetic-modification-therapies-market

Table of Contents:

Other Related Market Research Reports:

Guar Gum Market is Forecast to Cross US$ 1.5 Billion by 2024

High Content Screening Market to Grow US$ 1.10 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Here is the original post:
Genetic Modification Therapies Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape,...

Recommendation and review posted by Bethany Smith

Data Bridge Market Research has recently added a concise research on the Prostate Cancer Therapeutics Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated. As per study key players of this market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson

Prostate cancer therapeutics marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to reach a market value of USD 18.71 billion by 2027 while growing at a CAGR of 7.70% in the above-mentioned forecast period. Prostate cancer therapeutics market is growing due to factor such as increasing cases of prostate cancer and cardiovascular diseases.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific, Brazil, Peru, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Kuwait, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Major Market Competitors/Players:Global Prostate Cancer Therapeutics Market

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Increasing awareness among people regarding prostate cancer along with technological advancement in screening and diagnostic tests, rising preferences of healthy living will increased geriatric population will enhance the growth of the prostate cancer therapeutics market in the forecast period of 2020-2027. On the other hand, limited number of players, increasing pharmaceutical expenditure will further create new opportunities for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Increasing cost of the treatment and adverse impact of treatment along with less success rate will acts as a restraint factor for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Competitive Landscape and Prostate Cancer Therapeutics Market Share Analysis

Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to prostate cancer therapeutics market.

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Grab Your Report at an Impressive 30% Discount! Please click Here @

https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-prostate-cancer-therapeutics-market

Prostate Cancer Therapeutics Market Country Level Analysis

Prostate cancer therapeutics market is analysed and market size insights and trends are provided by country, drug class and distribution channel as referenced above.

The countries covered in the prostate cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Kuwait, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Peru, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prostate cancer therapeutics market due to increasing occurrence of prostate cancer and high mortality rate along with rising investment in research and development of advanced solutions while Asia-Pacific will witness a growth in forecast period of 2020-2027 because of increasing awareness among people regarding tumours and improvement in healthcare infrastructure in this regions.

The country section of the prostate cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Major Market Drivers and Restraints:

Reasons to Purchase this Report

Customization of the Report

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read more:
COVID-19 UPDATE: Prostate Cancer Therapeutics Market Increase In Research & Development In Oncology Therapeutic Area with Study Objectives,...

Recommendation and review posted by Bethany Smith

Prostate Cancer Therapeutics Market report covers many business strategies such as new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to amplify their footprints in the market. According to this report, the global market is anticipated to see a relatively higher growth rate during the forecast period. The market drivers and restraints have been explained in this industry report using SWOT analysis. The market share of major competitors on global level is also studied in the Prostate Cancer Therapeutics Market report where key areas such as Europe, North America, Asia Pacific and South America are covered in this market research report.

Prostate cancer therapeutics marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to reach a market value of USD 18.71 billion by 2027 while growing at a CAGR of 7.70% in the above-mentioned forecast period. Prostate cancer therapeutics market is growing due to factor such as increasing cases of prostate cancer and cardiovascular diseases.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific, Brazil, Peru, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Kuwait, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Major Market Competitors/Players:Global Prostate Cancer Therapeutics Market

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Increasing awareness among people regarding prostate cancer along with technological advancement in screening and diagnostic tests, rising preferences of healthy living will increased geriatric population will enhance the growth of the prostate cancer therapeutics market in the forecast period of 2020-2027. On the other hand, limited number of players, increasing pharmaceutical expenditure will further create new opportunities for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Increasing cost of the treatment and adverse impact of treatment along with less success rate will acts as a restraint factor for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Competitive Landscape and Prostate Cancer Therapeutics Market Share Analysis

Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to prostate cancer therapeutics market.

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-prostate-cancer-therapeutics-market

Prostate Cancer Therapeutics Market Country Level Analysis

Prostate cancer therapeutics market is analysed and market size insights and trends are provided by country, drug class and distribution channel as referenced above.

The countries covered in the prostate cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Kuwait, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Peru, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prostate cancer therapeutics market due to increasing occurrence of prostate cancer and high mortality rate along with rising investment in research and development of advanced solutions while Asia-Pacific will witness a growth in forecast period of 2020-2027 because of increasing awareness among people regarding tumours and improvement in healthcare infrastructure in this regions.

The country section of the prostate cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Major Market Drivers and Restraints:

Reasons to Purchase this Report

Customization of the Report

Read More @ https://www.databridgemarketresearch.com/reports/global-prostate-cancer-therapeutics-market

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Prostate Cancer Therapeutics Market with Rising Demand & Huge Application Potential from Industry by 2026 - 3rd Watch News

Recommendation and review posted by Bethany Smith

Global Prostate Cancer Therapeutics Market report covers many business strategies such as new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to amplify their footprints in the market. According to this report, the global market is anticipated to see a relatively higher growth rate during the forecast period. The market drivers and restraints have been explained in this industry report using SWOT analysis. The market share of major competitors on global level is also studied in the Global Prostate Cancer Therapeutics Market report where key areas such as Europe, North America, Asia Pacific and South America are covered in this market research report.

The market research data included in this Global Prostate Cancer Therapeutics Market report is analysed and forecasted using market statistical and coherent models. The key research methodology utilized here by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. This global market report additionally encompasses predictions utilizing a practical arrangement of suspicions and techniques. A lot of hard work has been put together and no stone is left unturned while generating this market research report. Global Prostate Cancer Therapeutics Market is a proficient and comprehensive report that focuses on primary and secondary market drivers, market share, leading segments and geographical analysis.

Global Prostate Cancer Therapeutics Market is expected to growing at a CAGR of 12.5% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Download Free PDF Sample Copy of[emailprotected]https://databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market,By Drug Type (Hormonal Therapy, Luteinizing Hormone-Releasing Hormone (LHRH) Agonist, Anti-Androgens, Immunotherapy, Targeted Therapy, Chemotherapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Major Market Competitors/Players:

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Major Market Drivers and Restraints:

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Competitive Analysis:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of prostate cancer therapeutics market for global, Europe, North America, Asia Pacific and South America.

Reasons to Purchase this Report

Order a Copy of This ResearchReport @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-prostate-cancer-therapeutics-market

Customization of the Report

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read this article:
Global Prostate Cancer Therapeutics Market Future Demand (COVID 19 Impact Analysis) & Growth Analysis with Forecast up to 2027 - 3rd Watch News

Recommendation and review posted by Bethany Smith

Data Bridge Market Research has recently added a concise research on the Clinical Laboratory Services Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated.

Clinical laboratory services marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2020 to 2027 and expected to reach USD 217,941.33 million by 2027 from USD 134,692.52 million in 2019. Rising demand for early and accurate disease diagnosis is the factors for the market growth.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-clinical-laboratory-services-market&captain

Clinical laboratory services is playing significant role to enable doctors to make appropriate clinical and diagnostic decisions across various levels of health care services. Increasing demand for diagnostic tests is augmenting the market growth as they are used for clinical diagnoses tests.

The major players covered in the report are:-

Mayo Foundation for Medical Education and Research (MFMER), Laboratory Corporation of America Holding, Quest Diagnostics Incorporated, Spectra Laboratories (A Subsidiary of Fresenius Medical Care AG & Co. KGaA), DaVita Inc., Eurofins Scientific, UNILABS, SYNLAB International GmbH, MIRACA HOLDINGS Inc., Sonic Healthcare, ACM Global Laboratories, amedes Group, LifeLabs, Alere (A Subsidiary of Abbott), Charles River, Siemens Healthineers AG, BioReference Laboratories, Inc., NeoGenomics Laboratories, Inc., KingMed Diagnostics, Genomic Health, among other players domestic and global. Clinical laboratory services market share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many business expansion and developments are also initiated by the companies worldwide which are also accelerating the growth of global clinical laboratory services market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for Clinical Laboratory Services through expanded model range.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-clinical-laboratory-services-market?utm_source=news&utm_campaign=Captain

Global Clinical Laboratory Services Market By Specialty (Clinical Chemistry Testing, Hematology Testing, Microbiology Testing, Immunology Testing, Drugs of Abuse Testing, Cytology Testing, Genetic Testing), Provider (Hospital-Based Laboratories, Independent & Reference Laboratories, Nursing and Physician Office-Based Laboratories), Application (Bioanalytical & Lab Chemistry Services, Drug Development Related Services, Drug Discovery Related Services, Toxicology Testing Services, Cell & Gene Therapy Related Services, Preclinical & Clinical Trial Related Services, Other Clinical Laboratory Services), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Market Trends and Forecast to 2027

Rising demand of clinical laboratory services across the world is one of the prominent factors for increasing demand of clinical chemistry testing. For instance, yearly in the U.K., the usually citizen has 14 tests completed by a laboratory specialist. However in the U.S., laboratory testing is the only highest-volume medical activity and approximately 13,000 million tests are performed per year. Hence, this factor has led the patients to shift towards clinical chemistry testing because it offers a wide range of tests which are performed in the clinical laboratory testing. In the current scenario the technological advancements boost the patients reach to laboratory testing, which is becoming gradually more precise and affordable. For instance, point-of-care testing (POCT) is regularly applied in hospitals and other healthcare practices, so the patients not need to travel to the clinical laboratories for testing. The increasing use of point-of-care testing has reduced demand tests which are conventionally executed at industry laboratories.

Rising demand of early and accurate disease diagnosis across the globe is one of the prominent factors for an upsurge demand of clinical laboratory services. For instance, in 2018, World Health Organization projected that projected that an estimated 1.8 million new cases and almost 861,000 deaths occur due to colorectal cancer (CRC). This factor has increased the number of clinical laboratories around the globe as Delays in accessing cancer care are very common in the late-stage presentation, especially in lower vulnerable populations and resource settings.

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-clinical-laboratory-services-market&captain

Table of Contents-Snapshot Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

Country Level Analysis, By Provider

North America dominates the clinical laboratory services market as the U.S. is leader in clinical laboratory services. In North America due to better advancement in products and services, this region is dominating the clinical laboratory services. North America accounts higher healthcare expenditure, especially in U.S. Asia-Pacific is growing with the highest CAGR due to increase in medical tourism as well as increase in population. Numbers of companies in emerging countries are increasing due to increase in demand for disease diagnosis in clinics, hospitals and other areas. Additionally, the increasing number of healthcare expenditure and increasing number of hospitals and clinical diagnostic laboratories in China and India upsurge demand of clinical laboratory services. The Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Read More @ https://www.databridgemarketresearch.com/reports/global-clinical-laboratory-services-market?utm_source=news&utm_campaign=Captain

Huge Investment by laboratory for Clinical Laboratory Services and New Technology Penetration

Global clinical laboratory services market also provides you with detailed market analysis for every country growth in life science industry with clinical laboratory services demand impact of technological development in laboratory services and changes in regulatory scenarios with their support for the clinical laboratory services market. The data is available for historic period 2010 to 2018.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Clinical Laboratory Services Market Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2026 - 3rd Watch News

Recommendation and review posted by Bethany Smith

The Global Biopreservation market report presents market dynamics focusing on all the important factors market movements depend on. It includes current market trends with a record from historic year and prediction of the forecast period. This report is a comprehensive market analysis of the Biopreservation market done on a basis of regional and global level. Important market analysis aspects covered in this report are market trends, revenue growth patterns market shares and demand and supply along with business distribution

Request For Sample Biopreservation Market[emailprotected]https://www.adroitmarketresearch.com/contacts/request-sample/645

Bio-banking is further divided into veterinary IVF, human sperm and human eggs whereas regenerative medicine is sub-divided into gene therapy, cell therapy and more. On the basis of product outlook, market is divided into laboratory information management system, media and equipment.

Biopreservation is the increase in the shelf life and developed safety of foods, using the controlled or natural antimicrobial or microbiota compounds. It is the ecological and harmful method to deal with food preservation problem and is getting the attention in the current years. Growth in the demand for the developed methods of preservation and is continuously increasing the spending on healthcare is expected to boost the biopreservation market.

Pharmaceutical companies, biotechnology firms and hospitals are gradually accepting the systems for the in-house storage of the samples and is projected to offer a substantial growth to the global biopreservation market. Increasing the investments in the R&D activities by the research communities and companies are motivated to develop the capabilities of the product is increasing the biopreservation market with large potential.

Make an enquire Before Buying This Report @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/645

Developments in the technology like virtual bio-banks are expected to experience a substantial increase in the application, results in the biopreservation market growth. Moreover, rise in the preference of maintaining the repositories of biological specimen in the regenerative medicine and organ transplantation has promoted the biopreservation industry. With the help of initiatives by government like International Society of Biological and Environmental Repositories to augment the standards of preservation, practices and bio-banking is increasing the possibility for the growth of biopreservation market during the forecast period.

Rise in the expenditure for healthcare is expected to develop the healthcare quality and developed products involve the facilities of biopreservation, by widening the growth of biopreservation market. Moreover, gene banks, bio-banks and hospitals are the substantial consumers for biopreservation industry are influencing the manufacturers to produce the technologically developed products of biopreservation to increase the outcomes of patient and enhance the biopreservation market in the coming future.

With the help of several initiatives by government in healthcare are providing the grants, contracts and funds for research results in offering the growth to R&D activities set by several companies. This results in increasing the opportunity for implementing the developed services of bio-preservation, is projected to boost the growth of biopreservation market over the forecast period. Growth in the investments of R&D by research communities and companies to expand their effective products, services and capabilities is anticipated to increase the growth of biopreservation market. For example, formation of Cooperative Human Tissue Network are addressing the measurement of bio-banking, illustrates the continuous efforts by the community of research.

Get More Information About This Report With[emailprotected]https://www.adroitmarketresearch.com/industry-reports/biopreservation-market

Geographically, regions involved in the development of biopreservation market size are Europe, North America, Latin America, Asia Pacific and Middle East & Africa. U.S biopreservation market is dominating the North America and is propelled to increase the biopreservation industry in the coming years. Asia Pacific is estimated to hold the largest biopreservation market share over the forecast period.

Key players involved in the global biopreservation market are LabVantage Solutions, Thermo-Fischer Scientific, Custom Biogenic Systems, Biomatrica, Qiagen and more.

Key Segments in the Global Biopreservation Market are-

By Cell Provider Outlook, market is segmented into:

By Application, market is segmented into:

By Product Outlook, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Biopreservation Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

See original here:
Biopreservation Market Analysis 2019-2025 Emerging Trends, Growth Drivers, Challengers, Services, Competitive Landscape and Regional Outlook &...

Recommendation and review posted by Bethany Smith

According to the latest report by IMARC Group, titled North America Hormone Replacement (HRT) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025, the hormone replacement market in North America reached a value of US$ 502.6 Million in 2019. Hormone replacement therapy (HRT) is the most effective treatment that is used to supplement the hormones present in low levels in the human body. This treatment is usually suggested for patients who are experiencing growth hormone deficiency, women nearing menopause and elderly who are suffering from hypogonadism.

Request Free Sample Report: https://www.imarcgroup.com/north-america-hormone-replacement-therapy-market/requestsample

HRT is considered to be useful in treating the symptoms of menopause like night sweats, hot flashes, vaginal dryness and sexual function. It also aids in minimizing the risk of cardiovascular diseases, colorectal cancer, vasomotor symptoms and osteoporosis. Apart from this, countries in the North America region support the medical transition. For instance, the Canadian Bar Association favors this process of altering primary or secondary sex characteristics through hormone therapy or a variety of surgical procedures, which in turn is boosting its demand across the region. Moreover, technological advancements, coupled with the increasing investments in research and development (R&D) activities to enhance the quality and efficiency of hormone replacement therapies, are further providing a thrust to the market growth. Looking forward, IMARC Group, expects the market to reach levels worth US$ 5.0 million by 2025 exhibiting a CAGR of 5.2% during 2020-2025.

Market Breakup by End-User:

Market Breakup by Regions:

Ask Analyst and Download Full Report with List of Figure: https://bit.ly/3ioPCze

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

If you want to need latest primary and secondary data (2020-2025) with Cost Module, Business Strategy, Distribution Channel, etc.. Click request free sample report. We deliver report with-in 24 hours.

Source: steemit

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US

IMARC Group30 N Gould St Ste RSheridan, WY 82801, USAEmail: [emailprotected]Tel No:(D) +91 120 433 0800Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

See the article here:
North America Hormone Replacement Therapy Market: Demand, Share, Size, Industry Trends, Analysis and Forecast during 2020-2025 - Jewish Life News

Recommendation and review posted by Bethany Smith

According to the latest report by IMARC Group, titled North America Hormone Replacement (HRT) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025, the hormone replacement market in North America reached a value of US$ 502.6 Million in 2019. Hormone replacement therapy (HRT) is the most effective treatment that is used to supplement the hormones present in low levels in the human body. This treatment is usually suggested for patients who are experiencing growth hormone deficiency, women nearing menopause and elderly who are suffering from hypogonadism.

Request Free Sample Report: https://www.imarcgroup.com/north-america-hormone-replacement-therapy-market/requestsample

HRT is considered to be useful in treating the symptoms of menopause like night sweats, hot flashes, vaginal dryness and sexual function. It also aids in minimizing the risk of cardiovascular diseases, colorectal cancer, vasomotor symptoms and osteoporosis. Apart from this, countries in the North America region support the medical transition. For instance, the Canadian Bar Association favors this process of altering primary or secondary sex characteristics through hormone therapy or a variety of surgical procedures, which in turn is boosting its demand across the region. Moreover, technological advancements, coupled with the increasing investments in research and development (R&D) activities to enhance the quality and efficiency of hormone replacement therapies, are further providing a thrust to the market growth. Looking forward, IMARC Group, expects the market to reach levels worth US$ 5.0 million by 2025 exhibiting a CAGR of 5.2% during 2020-2025.

Market Breakup by End-User:

Market Breakup by Regions:

Ask Analyst and Download Full Report with List of Figure: https://bit.ly/3ioPCze

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

If you want to need latest primary and secondary data (2020-2025) with Cost Module, Business Strategy, Distribution Channel, etc.. Click request free sample report. We deliver report with-in 24 hours.

Source: steemit

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US

IMARC Group30 N Gould St Ste RSheridan, WY 82801, USAEmail: [emailprotected]Tel No:(D) +91 120 433 0800Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

View original post here:
North America Hormone Replacement Therapy Market: Share, Industry Trends, Price, Size, Demand and Forecast to 2020-2025 - 3rd Watch News

Recommendation and review posted by Bethany Smith

For the first time in the Smithsonian Conservation Biology Institutes (SCBI) history, ungulate keepers celebrated the birth of a male Hartmanns mountain zebra at the Front Royal, Virginia, facility. The colt was born overnight July 2 to 6-year-old mother Mackenzie and 5-year-old father Rogan. He is the first offspring for both parents. Ungulate keepers are closely monitoring the colt, and they report that he appears to be nursing well and sticking close by Mackenzies side.

Before their arrival at SCBI, Mackenzie and Rogan received a recommendation to breed from the Association of Zoos and Aquariums Species Survival Plan (SSP). The SSP scientists determine which animals to breed by considering their genetic makeup, health, personality and temperament, among other factors. In October 2018, Mackenzie and Rogan were transferred to SCBI from the Elmwood Park Zoo in Pennsylvania and the Cleveland Zoo in Ohio, respectively. Females typically reach sexual maturity around 2 to 3 years of age, while males become sexually mature around age 4 or 5. The pair bred naturally in June and July of 2019; Hartmanns mountain zebra gestation is about one year.

Each zebra is a unique individual, and keepers are looking forward to seeing how the colts personality develops. While mother Mackenzie is feisty and a bit standoffish, father Rogan is quirky and easygoing. The colt lives with Mackenzie and an unrelated female, 7-year-old Xolani, in a herd. Since male zebras do not provide any parental care to their offspring, Rogan lives in a separate enclosure nearby. Although the colt sticks close by Mackenzies side now, keepers say they are excited to see the foal explore his surrounding and watch his curiosity grow. Over the next two months, the colt will start sampling grass and pellets.

As a public health precaution due to COVID-19, the Smithsonians National Zoo and Conservation Biology Institute is temporarily closed to the public.Animal keepers and veterinary staff remain working on site at the Zoo and SCBI to provide the usual highest quality care for the animals.Additional information on the Zoos COVID-19 response is posted to theZoos website. The Zoo will share updates on the colt on Facebook, Instagram and Twitter.

Hartmanns mountain zebras are a subspecies of the mountain zebra, which is one of three zebra species. Considered vulnerable by the International Union for Conservation of Nature, Hartmanns mountain zebras live in dry mountain habitats of Namibia. Unlike other zebra species, Hartmann's mountain zebras live in small herds, have vertical stripes on their neck and torso and horizontal stripes on their backside, and have a small fold of skin under their chin (called a dewlap). With less than 25,000 individuals left in the wild, the biggest threat to this species survival is habitat loss and fragmentation as the result of livestock production and agriculture.

The Smithsonians National Zoos legacy of conservation work extends beyond the public Zoo in Washington, D.C., to SCBI in Front Royal, Virginia. Scientists at SCBI study and breed more than 20 species, including some that were once extinct in the wild, such as black-footed ferrets and scimitar-horned oryx. Animals thrive in specialized barns and building complexes spread over more than 3,200 acres. The sprawling environment allows for unique studies that contribute to the survival of threatened, difficult-to-breed species with distinct needs, especially those requiring large areas, natural group sizes and minimal public disturbance.

SCBI spearheads research programs at its headquarters in Virginia, the Zoo in Washington, D.C., and at field research stations and training sites worldwide. SCBI scientists tackle some of todays most complex conservation challenges by applying and sharing what they learn about animal behavior and reproduction, ecology, genetics, migration and conservation sustainability.

# # #

Read the rest here:
Hartmann's Mountain Zebra Born at the Smithsonian Conservation Biology Institute - Smithsonian's National Zoo and Conservation Biology Institute

Recommendation and review posted by Bethany Smith

Animal models, especially mice, have given scientists valuable insights into the mechanisms behind countless human diseases. They have been instrumental to the discovery of drug targets, metabolic pathways, and gene function. Theyve helped to lay bare the basic biochemistry of metabolism, hunger, cognition, and aging. Because mice are, to a certain extent, miniature facsimiles of human anatomy and genetics, science has an array of tools at its disposal to manipulate and visualize their bodily processes in real time, in highly controlled settings.

But, as the recent Covid-19 pandemic has revealed, science doesnt always have the tools to minimize loss of animal life. As the pandemic took hold and academic research labs across the U.S. shuttered indefinitely, scientists were faced with an unprecedented animal care dilemma. Without the teams of veterinary nurses and technicians who usually attend to the animals daily, many labs were forced to resort to wholesale euthanasia. Some labs sacrificed hundreds of animals, and were criticized harshly for their management of their experimental colonies. Many started to consider more durable, long-term plans for preserving and storing their mouse lines.

In the lab where I work at the University of California, San Francisco, and where for the past two years Ive been the designated rodent surgeon, we were asked to euthanize all but our most irreplaceable mice. As new animal researchers, we are trained to sacrifice our mice humanely to give them a dignified death. Returning to lab after the shutdown to find rows of empty racks that once held cages of mice we had worked with for months was a shock, and it was hard to conjure dignity in that moment.

That experience led me to reflect on how we as a research community use animal models in biomedical research, and how we might better use them in the future. And Ive become increasingly convinced that the animal model of the future will live not in a cage but in a computer chip: By simulating biological systems rather than experimenting with them, we can make drug development and biomedical research safer, more efficient, and more effective.

This is not to say that researchers treatment of animals has been haphazard. Research in animal models is highly regulated. These regulations vary in austerity from country to country and institution to institution, but they revolve around a common set of principles known as the three Rs: Replace the use of animals when possible, reduce the number of animals used per experiment, and refine methods to minimize suffering and improve welfare.

As the recent Covid-19 pandemic has revealed, science doesnt always have the tools to minimize loss of animal life.

A few years ago, when I was a new mouse surgeon, the three Rs were the guiding tenets of a week-long course I took at the Ren Remie Surgical Skills Center in Almere, Netherlands. The centers founder, Ren Remie, advocated for meticulous surgical technique, held to the same standards of sterility and post-operative care as any human surgical procedure. But he was also a proponent of the thinking that longer-term strategies can hasten recovery time from infection and surgical procedures. For instance, Remie and other researchers advocate whats called environmental enrichment, a method that helps animals cope with the inherent stress of being isolated after a surgical procedure or during an experiment. The researchers place toys, nesting material, or other inanimate objects in the cage that allow the mouse to engage with its surroundings, similar to the way it would in the wild. Studies suggest that environmental enrichment may even promote wound healing in rats.

But the success of strategies like environmental enrichment highlights an inherent weakness of the animal research model: An animals behavior is often extremely sensitive to its environment, in ways that are difficult if not impossible to control. This raises a perennial issue in biomedical research of just how reliably conclusions drawn based on studies in mice can be faithfully applied to human disease treatment. For instance, rodents are housed in groups as a rule, but certain kinds of experiments and treatments require them to be isolated, triggering a stress response that could significantly affect their immune activation. Studies have shown that mice and rats who live with companions fare better against injury, stroke, and even tumor growth than their lonely counterparts. As a result, when mice studies ask questions about human diseases, the housing status of the mouse is often a confounding factor. Even slight variation in the ambient temperature of a mouses housing room can cause stress responses that affect experimental outcomes. This variability is one reason that treatments that seem promising in mice often produce underwhelming outcomes in human clinical trials.

One attractive complement to animal studies that may address some of these shortcomings is in silico, or on a chip medicine. In silico models apply computational modeling strategies to genomic data to predict physiological responses to drugs or other stimuli. Although they are far from being able to replicate the full complexity of a living, sentient being, the U.S. Food and Drug Administration has begun consider computer modeling-based strategies to update the cumbersome and costly clinical trial pipeline. Research with in vitro models, which attempt to replicate animal physiology in test-tube style experiments, have also shown promise. These efforts have given birth to projects like the Comprehensive in Vitro Proarrhythmia Assay initiative, which integrates modeling and in vitro strategies to evaluate the potential for new drugs to cause heart rate abnormalities

Likewise, in 2013, the European Commission assembled a consortium of research groups known as the Avicenna Alliance to unify academia and industry around a set of standards for computer modeling in medicine. Based in Belgium but comprised of independent organizations around the world, the goal of the Alliance is to enable virtual clinical trials whose results can be validated by the same kinds of rigorous standards that are applied to traditional clinical trials.

As the Avicenna Alliance envisions them, virtual clinical trials would be based on unique genetic models derived from individual patients, rather than on large, genetically variable sample groups. Conceivably, this could allow a researcher to simulate a patients unique response to a treatment strategy, capturing the effects of subtle variations in baseline metabolism, bodyweight, or underlying health conditions that might influence the patients treatment outcomes. It might also significantly reduce the time and expense traditionally required to usher a new drug or medical device from the lab bench to the clinic potentially lowering the barrier to care for large swaths of the population who cant afford the often-astronomical costs of life-saving medications.

In silico clinical trials, if and when they are realized, could also address the long-standing problem of sample bias in drug development. Demographically, clinical trials tend to be disproportionately White and, until recently, overwhelmingly male. They therefore dont fully capture the therapeutic value and potential risks that drugs present to the patients who eventually rely on them. If in silico strategies become widely adopted, theyll hold potential to both increase the efficacy of new drugs and expand access to treatment.

The ethical debate around the use of animals in research has roiled for hundreds of years and will likely continue to do so. But what the Covid-19 outbreak has made clear is that there are severe weaknesses in the current animal model paradigm. As experiments have come to a halt during the coronavirus lockdowns, researchers have been given time to consider new, more sustainable approaches to discovery. Hopefully, we will look beyond the short-term technical challenges that will inevitably accompany the resumption of business as usual and gaze further afield, toward more humane, more modernized approaches to doing science.

Lindsay Gray is a lab manager at the University of California, San Francisco.

View post:
In the Future, Lab Mice Will Live in Computer Chips, Not Cages - Undark Magazine

Recommendation and review posted by Bethany Smith

We hold these truths to be self-evident, that all men are created equal, that they are endowed by their Creator with certain unalienable Rights, that among these are Life, Liberty, and the pursuit of Happiness.

Nothing fills me with a greater awe and sense of purpose than this ideal. It is the essence of my lifes work in teaching peace and justice. As an educator I believe that all of humanity is improved in recognizing equality in basic human rights and delivering on promises of equal opportunity. Unfortunately, however, this purpose doesnt generally register as patriotism; my country has failed to take equality seriously. Instead we promote mythology, an ongoing white liethe farcewhich asserts an America created as a model for humankind by wise and justice-minded Founding Fathers.

Early challenges to that myth by eloquent victims of the American reality include one from July 5, 1852, when former slave Frederick Douglass addressed the nation with his question, "What to the Slave is the Fourth of July?" at an Independence Day celebration:

Fellow-citizens! I will not enlarge further on your national inconsistencies. The existence of slavery in this country brands your republicanism as a sham, your humanity as a base pretense, and your Christianity as a lie.

Can we imagine that in 2020 minorities and persons of color are still asking for access to the American Dream, but also for permission to live? The nightmare of injustice is structural, systematic, intentional, and persistent, but were tolddecade after decadethat it is necessary to be patient and it is only a few bad apples.

We never acknowledge that the bad apples, just like the injustice, are produced in every city on every day.

The descendants of slaves carry the genetics raped into their family trees. Our streets are filled with signs honoring the rapists names. The farce says these ignoble criminals should be celebrated.

We do not teach that George Washingtons dentures were made from human teeth or ivory, tell the white lie that they are made out of wood instead of admitting there is a good chance they were purchased at cut-rate prices from slaves or, in the very best case, from desperately poor people.

We do not teach that while Benjamin Franklin eventually saw the moral need to abolish slavery, the equality pronounced in declaring independence did not extend to the slaves he owned until 1781. The White House was built with slave labor. Thomas Jefferson fathered children with Sally Hemings. How does a 16-year-old slave end up pregnant by her owner?

This social malady is present in the jokes about nooses and the insistence of those who tell them. Forget that there have been thousands of lynchings and that the racialized terror continues to traumatize communities of color. This buffoonery insists that it is not racist to joke, even when the jokes are about hate crimes. Some are inspired to mock the murder of George Floyd, posting photos of themselves kneeling on each other's necks to mimic the murder of George Floyd, or to make jokes about not being able to breathe

The problems are not isolated. Messages of animus come from everywhere, the White House with its ongoing bigotry has no problem making clear that people of color should go back to where they came from regardless of whether or not they were born in the US. Police departments have used violent militaristic responses to peaceful Black Lives Matter gatherings, with some officers declaring they are ready for a civil war; We are just going to go out and start slaughtering them f------ n------.

Sanctioning the history of the United States of America is always challenging. Sanction, contranym (a word with two different and contradictory meanings), is understood as both a threatened penalty and also as approval. Elaborate displays of patriotism tend toward the later, when progress demands the former. I am calling for negative sanctions on teaching American history from the point of view of white male propertied slaveowners. I would positively sanction teaching American history by equally honoring all the voices from all groups.

A gritty reality: A bunch of wealthy white slave owning capitalists got tired of paying taxes. They wrote a Constitution and created an Electoral College to protect the slave trade. It is time that we started telling the truth about the past and were honest about the present. A racist bully lost the popular vote by 3 million votes but occupies the office of the President because of an institution designed to perpetuate inequality. We no longer have signs that say colored but we see the same outcomes in everything from life expectancy and the lethality of the coronavirus to wealth and incarcerations disparities. We have never atoned or made reparations for this past, it is time to take equality seriously.

Wim Laven, Ph.D., syndicated by PeaceVoice, teaches courses in political science and conflict resolution.

Continue reading here:
The Farce of July | Columnists - Anchorage Press

Recommendation and review posted by Bethany Smith

A 3,960-g female infant is born at 37 weeks of gestation to a 25-year-old gravida 2, para 1-0-0-1 woman via vaginal delivery. The pregnancy had been complicated by a history of depression not requiring pharmacologic treatment, a urinary tract infection treated successfully, fetal abdominal distention and ascites, and polyhydramnios requiring 3 procedures for amniotic fluid reduction. Noninvasive prenatal testing and -fetoprotein levels were normal.

Apgar scores are 6 and 8 at 1 and 5 minutes, respectively. The infant has decreased respiratory effort but improves with continuous positive airway pressure and is weaned to room air while in the delivery room with no further respiratory concerns. Because of the significant abdominal distention, the patient is transferred to the NICU where the physical examination findings are significant for abdominal distention, an abdominal circumference of 38 cm, palpable bowel loops, and absent bowel sounds. Other significant findings include bilateral webbing of the second and third toes and bilateral fusion of

Read more from the original source:
Case 2: Term Female Newborn with Prenatal Diagnosis of Abdominal Distention and Ascites - AAP News

Recommendation and review posted by Bethany Smith

The coronavirus pandemic is a daily reminder of the far-reachingconsequences of apathogens successful invasion of human cells. And, as a new University of Toronto study on bacterial toxins shows, it does not take much for these encounters to turn deadly.

The research found that two almost identical bacterial toxins cause distinct illnesses diarrhea and fatal toxic shock syndrome by binding unrelated human receptors. It also highlights a mechanism by which pathogens have evolved distinct receptor preferences to infect different organs.

I always think of bacterial toxins as fascinating machines of death in how they find new ways to enter host tissue, saysMikko Taipale, an assistant professor of molecular genetics at the Donnelly Centre for Cellular and Biomolecular Research.

Taipaleco-led the study,published recently in the journalCell, withRoman MelnykandJean-Philippe Julien, both senior scientists at the Hospital for Sick Children and faculty members in U of Ts department of biochemistry.

Many are familiar withClostridium difficile, a gut-dwelling bacterium that can cause diarrhea. Lesser known is its close relative,Paeniclostridium sordellii, which also lives in the gut and in the female reproductive tract. Infections are rare but fatal and can occur when the bacterial toxin escapes into the bloodstream, during birth for example, and spreads into the lungs and other organs.

Both species are thought to be part of the microbiome, the bodys resident bacteria, but its not clear why they harm some people and not others.

The toxin released byC. difficileacts through Frizzled receptor proteins, which play a role in tissue regeneration. Yet, whileP. sordelliiproduces a similar toxin, it does not bind in the same way so the researchers set out to investigate.

They took an unbiased approach by systematically switching off every gene in human cells and exposing them to theP. sordelliitoxin. Cells that survived turned out to lack genes encoding cell surface proteins called semaphorins, and other experiments confirmed that two members of this class, Semaphorin6A and Semaphorin6B, are indeed the receptors for the toxin. Both receptors are present in the lungs, as expected, though their role there remains unclear.

Knowing the receptor opens the door to finding treatment. The researchers were able to halt infection in mice by co-injecting the toxin with purified semaphorin fragments, which bound and neutralized the toxin before it could reach the real receptors.

But the finding led to more surprises.

Like Frizzled, semaphorins play important roles in the body most notably in developing the nervous system, where they help guide projecting nerve fibers. Even more surprising was that it binds a receptor with no structural resemblance to Frizzled.

Here we have two toxins that are so similar to each other, but they use completely different receptors, says Taipale. We did not expect to find that.

The reason is a tiny differencebetween C. difficileandP. sordellii in particular, the surface though which both toxins contact their receptors, as revealed by cryo electron microscopy. Each toxin protein is composed of about 2,500 amino-acids and the researchers were able to pinpoint those that directly engage with the receptor. Swapping a mere 15 of these amino acids between the two toxins was sufficient to switch receptor preference. In other words, they created a P. sordellii toxin that targeted Frizzled and vice versa.

We were floored when we saw that the toxins shared a surface that each evolved to uniquely interact with distinct cells, says Julien.

It appears that, while the rest of the toxin is under strong evolutionary pressure to remain unchanged, the receptor-binding surface is free from such constraints. This allows toxins to evolve into variants that bind new receptors to invade other tissues and hosts.

Receptor switching is not unique to bacteria, however. SARS-CoV-2 and coronavirus strains that cause common cold use the same part of the now famous spike protein to bind to diverse receptors, which might explain differences in disease severity.

This is a nice example of how viruses and bacteria from completely different domains of life have found similar molecular tactics to change their receptor targets in human cells, says Taipale.

It also reminds us how much cool biology one can find in the microbial world.

The research was supported by the CIFAR Azrieli Global Scholar program, the Ontario Early Researcher Awards programand the Canada Research Chairs program.

More:
Study by U of T researchers reveals how bacterial toxins evolve to cause new illnesses - News@UofT

Recommendation and review posted by Bethany Smith

Stem cells have been holding great promise for regenerative medicine for years. In the last decade, several studies have shown that this type of cell, which in Spanish is called mother cell because of its ability to give rise to a variety of different cell types, can be applied in regenerative medicine for diseases such as muscular and nervous system disorders, among others. Researchers and stem cell pioneers Sir John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for this idea. However, one of the main limitations in the application of these cell therapies is the quality of the stem cells that can be generated in the laboratory, which impedes their use for therapeutic purposes.Now, a team from the Cell Division and Cancer Group of the Spanish National Cancer Research Centre (CNIO), led by researcher Marcos Malumbres, has developed a new, simple and fast technology that enhances in vitro and in vivo the potential of stem cells to differentiate into adult cells. The research results are published in The EMBO Journal.

In recent years, several protocols have been proposed to obtain reprogrammed stem cells in the laboratory from adult cells, but very few to improve the cells we already have. The method we developed is able to significantly increase the quality of stem cells obtained by any other protocol, thus favouring the efficiency of the production of specialised cell types, says Mara Salazar-Roa, researcher at the CNIO, first author of the article and co-corresponding author.

In this study, the researchers identified an RNA sequence, called microRNA 203, which is found in the earliest embryonic stages before the embryo implants in the womb and when stem cells still have their maximum capacity to generate all the different tissues. When they added this molecule to stem cells in the laboratory, they discovered that the cells ability to convert to other cell types improved significantly.

To corroborate this, they used stem cells of human and murine origin, and of genetically modified mice. The results were spectacular, both in mouse cells and in human cells. Application of this microRNA for just 5 days boosts the potential of stem cells in all scenarios we tested and improves their ability to become other specialised cells, even months after having been in contact with the microRNA, says Salazar-Roa.

According to the study, cells modified by this new protocol are more efficient in generating functional cardiac cells, opening the door to an improved generation of different cell types necessary for the treatment of degenerative diseases.

Malumbres, head of the CNIO Cell and Cancer Division Group, says: To bring this asset to the clinic, collaboration with laboratories or companies that want to exploit this technology is now necessary in each specific case. In this context, Salazar-Roa recently participated, in close collaboration with the CNIOs Innovation team, in prestigious innovation programs such as IDEA2 Global of the Massachusetts Institute of Technology (MIT) and CaixaImpulse of the la Caixa Foundation, from which they also obtained funding to start the development of this technology.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Quick and Simple Technology Enhances the Potential of Stem Cells To Differentiate Into Adult Cells - Technology Networks

Recommendation and review posted by Bethany Smith

LOS ANGELES As medical experts learn about the novel coronavirus, which continues to exhibit an array of ever-evolving symptoms and long-term effects, researchers have found that the deadly illness can have deleterious impacts on the heart and brain.

A recent study published on June 25 in the journalCell Reports Medicine, found that while COVID-19 is commonly known as a respiratory illness, the disease has also been known to instigate inflammatory responses in the body which can negatively affect the function of ones heart and brain.

According to the study, researchers observed SARS-CoV-2 infecting human heart cells that were grown from stem cells in a lab. Within 72 hours of infection, the virus managed to spread and replicate, killing the heart cells.

The researchers brought up the particularly alarming possibility that if COVID-19 can infect the heart cells in a laboratory setting, it could possibly infect those specific organs, prompting the need for a cardiac-specific antiviral drug screen program.

And those concerns are not unwarranted, according to doctors and other researchers who have been observing and studying the wide range of health problems and negative outcomes that appear to come with the not-yet-fully-known territory of the novel virus.

The most common coronavirus symptoms are fever, a dry cough and shortness of breath and some people are contagious despite never experiencing symptoms. But as the virus continues to spread, less common symptoms are being reported, including loss of smell, vomiting and diarrhea, along with a variety of skin problems and harmful neurological effects.

A recentreportfromDr. Robert Stevens, M.D., the associate director of the Johns Hopkins Precision Medicine Center of Excellence for Neurocritical Care, said that coronavirus patients are continuously experiencing a wide range of disconcerting effects on the brain.

Some of the neural symptoms, according to Johns Hopkins, include:

Patients are also having peripheral nerve issues, such as Guillain-Barr syndrome, which can lead to paralysis and respiratory failure, wrote Stevens. I estimate that at least half of the patients Im seeing in the COVID-19 units have neurological symptoms.

While medical experts have continuously repeated that more is still being discovered about the virus, Stevens listed some possibilities on how COVID-19, a respiratory illness, is making its way to the brain.

The first possible way is that the virus may have the capacity to enter the brain and cause a severe and sudden infection. Cases reported in China and Japan found the viruss genetic material in spinal fluid, and a case in Florida found viral particles in brain cells, Stevens wrote.

He added that viral particles in the brain and spine may occur when the virus enters the body through a patients bloodstream or nerve endings.

The second possibility is that the bodys immune system has an overreaction to the virus, causing severe inflammatory responses that cause organ and tissue damage.

The third theory is the erratic physiological changes the disease causes in the body, which involve extremely high fever and low oxygen levels in the blood, result in harmful effects to the brain.

Stevens added that there has been an abnormal observance of blood clotting that has caused some coronavirus patients to suffer strokes. A stroke could occur if a blood clot were to block or narrow arteries leading to the brain, he said.

Another illness that has been known to impact the brain in patients with COVID-19 is currently being studied by Dr. Mady Hornig, an immunologist and professor of epidemiology at Columbia University.

Hornig said that Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an illness that has been found in patients who have recovered from coronaviruses such as SARS.

TheCenters for Disease Control and Preventioncites a 2015 report from the nations top medical advisory body, the Institute of Medicine, which says that an estimated 836,000 to 2.5 million Americans suffer from ME/CFS.

The CDC says that people with ME/CFS experience severe fatigue, sleep problems, as well as difficulty with thinking and concentrating while experiencing pain and dizziness.

Hornig said SARS-CoV-1 and MERS have been associated with longer-term difficulties, in which many people appeared to have symptoms of ME/CFS.

Hornig is currently researching the long-term effects of COVID-19, and has been confronted with an array of concerning symptoms that have persisted in patients, as well as herself.

She can personally attest to the variety of symptoms that have been reported in coronavirus patients, ever since she began to experience her own COVID-19 symptoms in April that have continued to impact her daily life for the past few months.

She has also experienced cardiac complications while dealing with the illness.

Since getting sick, Hornig said shes had to carry a pulse oximeter with her, a device which registers her pulse since she began to have tachycardia episodes when her fever began to decline. Tachycardia is a condition that can make a persons heart beat abnormally fast, reducing blood flow to the rest of the body,according to the Mayo Clinic.

Hornigs most recent episode was on June 22. Her pulse registered at 135 beats per minute, which she said occurred just from her sitting at her computer. She said a normal pulse for someone her age would be around 60-70 beats per minute.

The findings on the novel virus potential effects on the heart and brain come as the CDC continues to update itslistof coronavirus symptoms and high-risk conditions for COVID-19 complications.

Notably, the CDC also removed the specific age threshold from the older adult classification. CDC now warns that among adults, risk increases steadily as you age, and its not just those over the age of 65 who are at increased risk for severe illness, the agency wrote.

Johns Hopkins has noted that younger patients in their 30s and 40s are reportedly having strokes as a result of COVID-19.

It may have something to do with the hyperactive blood-clotting system in these patients, Stevens said. Another system that is hyper-activated in patients with COVID-19 is the endothelial system, which consists of the cells that form the barrier between blood vessels and body tissue. This system is more biologically active in younger patients, and the combination of hyperactive endothelial and blood-clotting systems puts these patients at a major risk for developing blood clots.

But Stevens cautioned that more conclusive data is needed before the medical community can say with assurance that younger people are particularly susceptible to strokes caused by the novel coronavirus.

It is also plausible that theres an increase in stroke in COVID-19 patients of all ages, Stevens said.

34.052234-118.243685

Go here to read the rest:
Its not just the lungs: COVID-19 can affect the brain and heart of those infected, researchers say - WITI FOX 6 Milwaukee

Recommendation and review posted by Bethany Smith

Transparency Market Research (TMR) has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~ US$ 5 Bn in 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Planning To Lay Down Future Strategy? Request Brochure Of Cell Separation Technology Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1925

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

To Obtain All-Inclusive Information On Forecast Analysis Of Cell Separation Technology Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Request For Covid19 Impact Analysis

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1925

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration (CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

View original post here:
Cell Separation Technology Market by Leading Manufacturers, Demand and Growth Overview 2019 to 2027 - Jewish Life News

Recommendation and review posted by Bethany Smith

IVF is expensive! Here's a break-down of all the costs associated with the fertility process, which explains why it's so pricey in the first place.

Infertility is a tough emotional and physical experience and a record number of families are using Invitro Fertilization (IVF) to have babies. A report by Pew Research Center suggests that the number of assisted reproductive technology (ART) births in the UShas gone up threefold since 1996. Moreover, one in three American adults has used or knows someone who has sought after some form of fertility treatment. That is 12.7% of women aged 15-49, as stated by the CDC. IVF is the most popular form of ART treatment which apparently, is more expensive in the United States than anywhere else.

View this post on Instagram

Have you ever wondered how embryos are created in the lab? ( ): Using Standard IVF means to place both gametes, previously treated to facilitate this process, together in a petri dish. We let nature do its part and spermatozoon will run to the oocyte in the culture media drops and, if everything goes well, one day later we will have a zygote (the single cell made by the fusion of both gametes). ( ): With this process, we take every spermatozoon one by one, after a proper process, and we physically inject it inside the oocyte emulating thus the natural process. If everything goes well, one day later we will have the zygote. This zygote with only one cell will start cleavage and will increase its cell number day by day. Thus, on the day 2 of the embryo, we expect to have, average, 2-4 cells, on the 3rd day, average, 6-12, on day 4 cells should start compacting and become a new structure called Morula and fifth day, we should have a blastocyst. Feel free to ask additional questions and check our webpage - http://www.geomedicalart.com #ivfjourney #ivf #invitro #invitrofertilization #fertility #fertilityjourney #embryo #health #georgia

A post shared by GeoMedicalART (@geomedicalart) on Jul 2, 2020 at 12:05am PDT

IVF is a fertility treatment that uses a female's eggs and a male's sperm. The process involves combining the extracted egg and retrieved sperm in a laboratory dish. The mixture forms an embryo in a process called insemination, and the fertilized is then transferred to your uterus, three to five days after fertilization.

This ART technique is applied to treat infertility patients who have male factor infertility, unexplained sterility, blocked or injured fallopian tubes, ovulation illnesses, and couples with genetic disorders.

RELATED: Paid Surrogacy Is Illegal In Canada - What Other Fertility Options Are There?

Figures from Advanced Fertility Care shows that live birth success rates in the US for each IVF round is 54.9% for patients below 35 years. The percentage decreases as a person gets older, with patients below 40 years having a success rate of 21.2% and those above 42 years achieving zero live births.

In the United States, the average cost for one IVF round is $12,000 without including the cost of medication. However, the cost varies and may be as high as $15,000 or as low as $10,000. Likewise, the cost of the medication ranges between excesses of $3,000 andas low as$1,500. Thus, on average, a patient can spend up to $20,000 for one IVF cycle, and up to $60,000 for three full IVF cycles.

The treatment is quite pricy primarily because the process involves many stages of preparation before, and after the treatment that tallies up over time. Patients pay for the IVF procedure itself, in addition to regular consultations, hormone medications, and the prospect of having to undergo more than one IVF cycle.

Many factors determine the cost of IVF, which includes the patients age, medical history, and the type of procedure. The costs from the procedure are determined by the injectables, specialist care, egg and sperm retrieval, genetic testing, insemination, storing and caring for the fertilized egg (embryo), and so on. Additionally, a patients personal choices can affect the cost as well. For instance, if a person has a low pain threshold, there will be an extra cost for getting sedated or anesthetized for egg retrieval.

On the whole, finances are a big consideration when it comes to IVF, which takes 10 t0 12 days of medication, and an additional five days to grow the embryo and placing it inside the uterus. The most expensive part of IVF is when a couple opts for a pregnancy carrier. If you add the legal and agency fees, IVF costs, and reimbursement to the pregnancy carrier, the cost can vary from a low of $50,000 to a high of $100,000.

Resorting to an IVF can look like too big a step, but there are ways you can save money on IVF.

Do A Mini-IVF.The bulk of expenses for IVF treatments go to the injectables used to stimulate the growth of an egg. This medication can be very pricy, but there is a way of doing IVF with fewer meds through Mini-IVF, short for minimal stimulation IVF. Although Mini-IVF has not caught on in America, it is a procedure that reduces IVF treatment costs by using much fewer injectables. However, this method is not recommended for everyone as it could lessen the chances of success for some. Therefore, seek guidance from a clinic that specializes in the procedure if you choose Mini-IVF treatment.

Thorough Financial Planning.How much money will you need? Get detailed information concerning every aspect of the treatment and cost. You will need to know what is factored into the total cost and what is not counted in. Then, begin saving months before, and read your insurance plan to see if you are eligible for partial coverage.

Choosing An IVF Clinic.Find the clinic that will provide the treatment you need at a price you can afford. Likewise, find a clinic that offers exceptional treatment packages with guarantees and great success rates, to avoid having to undergo more than one IVF round.

NEXT:Celebrities You Didn't Know Had Fertility Issues

Sources: webmd.com, cnyfertility.com, creatingafamily.org, medicalexpress.com.

Shawn Johnson Blames Past Drug Use & Eating Disorder For Her Miscarriage

I have been a writer since 2012, and have enjoyed the journey thus far. When I am not busy writing like there's no tomorrow, I enjoy spending time with my three daughters and watching Netflix.

Read more here:
Where Is Your Money Really Going During IVF? | BabyGaga - BabyGaga

Recommendation and review posted by Bethany Smith

Nanotechnology is poised to revolutionize the diagnosis and treatment of patients with type 1 diabetes.

According to the WHO, in 2016, an estimated 1.6 million deaths were directly caused by diabetes. It is a chronic disease that occurs when the body is unable to produce or process a hormone called insulin, which helps regulate blood sugar levels.

Of the three major types, type 1 diabetes has proven to be the most problematic in terms of providing patients with a timely diagnosis, as patients may be asymptomatic for long periods of time with a sudden onset of symptoms well into the diseases progression.

Currently, type 1 diabetes can be diagnosed at any age, but it is mostly found in children and adolescents. Once diagnosed, patients also have a high risk of diabetes-related complications, as well as other autoimmune diseases, such as hashimotos thyroiditis or celiac disease. Therefore, early diagnosis and treatment could prevent the progression of type 1 diabetes.

At present, the diagnosis of type 1 diabetes depends on the detection of blood glucose levels and islet autoantibodies, which are markers that appear when insulin producing islet cells clusters of hormone producing cells in the pancreas are damaged. But the function of the patients cells have likely already been severely damaged by the time they receive a diagnosis.

As more and more people suffer from type 1 diabetes of the 422 million people worldwide diagnosed with diabetes in 2016, roughly 5% were categorized as type 1 the importance of early diagnosis and the urgency of effective treatments becomes ever more important. However, recent medical methods for the early diagnosis of type 1 diabetes are still limited. So, its important to develop new methods for early diagnosis and treatment.

Nanomedicine is an emerging field and provides a promising and more effective alternative to diagnose type 1 diabetes, and stands to revolutionize treatment for patients. Experts in this field, Dr. Yuanzeng Min from the School of Chemistry and Material Science at the University of Science and Technology of China (USTC) and Dr. Jianping Weng, a clinician from the First Affiliated Hospital of USTC discuss the findings in a recent reviewpublished in WIREs Nanomedicine and Nanobiotechnology.

Magnetic resonance imaging (MRI) has in itself revolutionized imaging in medicine. It takes advantage of powerful magnets to make a detailed internal picture of the body and helps doctors diagnose otherwise unseen disease or injury. To improve this technique and make it more suitable to diagnosing patients with type 1 diabetes, scientists have explored using common biomarkers of the disease, such as inflammation, and enhancing physicians ability to detect them in MRI analysis using helper materials. In this sense, nanomaterials have been shown great promise in facilitating the accumulation of imaging substrates at the targeted site, thus improving the quality of MRI imaging and the accuracy of diagnosis.

An excellent example of this is the clinical use of the nanoparticle ferumoxtran-10 or ferumoxytol. In clinical studies, there was an observed increase in pancreatic accumulation of this imaging nanoparticle in inflamed islets of type 1 diabetes patients in comparison to a healthy control group. This method is non-invasive, and the imaging materials are readily metabolized by the body without harmful side effects. This technique has been ground-breaking in visualizing insulitis, an inflammatory lesion and an early stage marker of type 1 diabetes.

Type 1 diabetes is classified as an autoimmune disease in which insulin-producing cells are destroyed by the bodys own immune system, and is affected by a number of factors, such as genetics, environment and metabolism, among others. The downregulation of the overactive immune cells that kill the insulin-producing cells has been gathering more and more attention in the medical and research community.

Studies have shown that nanoparticles have the beneficial characteristics of high drug loading and are capable of being targeted to a specific location in the body, minimizing harmful side effects usually observed in these types of therapies. Scientists have used loaded nanoparticles to carry antigenic peptides or pMHC (peptide major histocompatibility complex) to suppress the bodys immune response so that the immune cells no longer attack cells. Research has also explored encapsulating cytokines or other synthesized molecules to modulate the immune system into the nanoparticles, which could be locally administered along with modulating immune cells, such as T cells or APCs (antigen presenting cells).

Significant progress in the development of sophisticated nanotechnologies has also been seen in the past 10 years for immunotherapy and islet transplantation in type 1 diabetes. Nanotechnology has played a significant role in islet transplantation by encapsulating healthy cells with biomaterials as most of the insulin-producing cells are destroyed by the patients own immune system. The biomaterials also protect the transplanted cells from immune exclusion. In addition to avoiding a deleterious host response, encapsulated islets must receive an adequate nutrient supply and positive extracellular cues in order to survive and functionin vivo.Thus, while using nanotechnology to encapsulate cells, it alsorequires as little interference as possible with the generation of new blood vessels in the encapsulation. This is usually achieved by improving the mechanical rigidity, charge distribution, morphology, and other related parameters of the nanomaterials.

While great strides have been made, limitations in the application of nanotechnology in diagnosis and treatment of type 1 diabetes remain. For example, some nanoparticles are not specifically target islets, their production process can be complicated, and the cost is high. However, their application in this area of medicine has only just begun, and we are beginning to see the benefits of this research in clinical trials.

With research in type 1 diabetes and the development of nanotechnology, these problems will hopefully one day be solved. We believe that in the next 10-20 years there will be high chance of this type of therapy used regularly in the clinical diagnosis and treatment oftype 1 diabetes patients.

Written by: Yuanzeng Min and Jianping Weng

Reference: Wen Pan, et al. Nanotechnologys application in Type 1 diabetes. WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/wnan.1645

View original post here:
Earlier diagnosis and better treatment for type 1 diabetes - Advanced Science News

Recommendation and review posted by Bethany Smith

Depression has been shown to be prevalent during menopause, affecting as many as 70 per cent of women transitioning into menopause, say researchers.The study, published in the journal of The North American Menopause Society (NAMS), not only confirms the high prevalence of depression but also the greatest risk factors for it in postmenopausal women, as well as any relationships with anxiety and fear of death. "The findings are consistent with existing literature and emphasize the high prevalence of depressive symptoms in midlife women, particularly those with a history of depression or anxiety and chronic health conditions," said study researcher Stephanie Faubion, NAMS medical director.With the decrease in hormone production during menopause, women are more prone to a number of psychological problems, including depression, anxiety, irritability, nervousness, sadness, restlessness, memory problems, lack of confidence and concentration, and a loss of libido.

At the same time, as women age, the fear of death becomes more pronounced.

Depression and anxiety, which are the most common psychological problems that occur during the menopause transition, likely increase that fear, the researchers said.

For the current findings, the research team picked 485 postmenopausal Turkish women aged between 35 and 78 years.

The researchers sought to determine the frequency of depressive symptoms in postmenopausal women, the variables affecting it, and the levels of anxiety and fear of death.

They then evaluated the relationship between all these variables and postmenopausal depression.

They found that depression in postmenopausal women is a common and important health problem that requires further study.

In this specific study, 41 per cent of the participants were confirmed to experience some form of depression.

bu/rs/

Read more from the original source:
Going through menopause increases risk of depression in 70% women, says study - Times of India

Recommendation and review posted by Bethany Smith

Today the whole world is focusing only on COVID-19 pandemic. The virus is the common topic now for every discussion, either official or non-official. But most of these talks are about COVID-19 patients and the potential drugs. And hardly anybody talk about the emotional and physical challenges that doctors on COVID-19 duty are going through, or for that matter, their health. Today, India is celebrating the National Doctors Day to acknowledge the services of doctors and their huge contribution to medical advancement. The day is also observed to pay tribute to legendary physician Dr. Bidhan Chandra Roy (Dr. B C Roy), who was also the second Chief Minister of West Bengal. As we thank doctors for providing us with selfless service and health care today, lets also asked them about their health, and how are theyre managing the work and family life amidst the pandemic. Also Read - Doctors' Day 2020: Help your doctor treat you better in the era of teleconsultation

We have spoken to four doctors a cardiologist, a pulmonologist, a diabetologist and a general practitioner to get a rough idea about what doctors are doing to maintain their work-life balance and keep themselves strong and healthy amidst the pandemic. Here is what the four doctors say: Also Read - Doctors Day 2020: Expert tips for patients and physicians to get along with each other

Dr. TS Kler is the Chairman of PSRI Heart Institute in Delhi and a recipient of the prestigious Padma Bhushan Award. Prior to this, Dr. Kler has served as Head of Cardiac Sciences Department at the Fortis Flt Lt Rajan Dhall Hospital in Vasant Kunj. Lets hear from him about things he does to stay healthy and the challenges he is facing amidst the pandemic. Also Read - Doctors Day 2020: What do physicians fear and expect while treating COVID-19 patients?

Things you do to maintain work-life balance: As far as maintaining work-life balance is concerned, my formula is simple, have a positive attitude towards life and then everything becomes easier. I dont take unnecessary worries, worrying too much is a pathological reaction. If you keep worrying about things, your performance decreases, your decision-making abilities become poor. On the other hand, when your mind is free from worries, you think rationally in any given situation that may help you deal with any problem in life. Similar is my attitude with COVID-19, which a big challenge for everybody. Yes, the chances of getting exposed to the virus are much more for doctors and health care workers as compared to others, but you have to take that challenge. I have been going to the hospital throughout the lockdown period without taking a single day leave. Im a cardiologist and there are always patients who need urgent care and they cannot be left alone. There are always emergency cases. We are also offering telemedicine options for those who dont need hospitalization. In my family, there are only four us my wife and our two sons. My wife is also a doctor and she is also playing a huge role in fighting the COVID-19 pandemic. My elder son is an engineer and my younger son is also a doctor and he has been posted in the COVID ward. As there are three doctors in the family, the evening discussion is mostly on COVID nowadays. And we all understand the demands of our job as a doctor and our responsibilities towards society. In fact, I keep telling my colleagues that we dont have any excuses at all to be scared of COVID or not to go to the hospital and see patients. If our patients need us, we have to go and see them.

Things you do to keep your heart healthy: I walk at least 10 km a day. I use an app called health application that records how much I have walked daily, every month and every year. So, based on the figure shown in this app, last year I walked 3842 km, which is more than the distance from Srinagar to Kanyakumari. You can do exercise any time whichever convenient for you but I prefer the morning time. I get up at 5 am in the morning and by 5:45 am I am out in the park. Exercise to me is a passion, its my addiction. I also do yoga regularly. We organize a regular yoga programme in my home, three days a week. When it comes to diet, I eat a lot of green vegetables and fruits. I am a non-vegetarian but I keep non-veg consumption very low. Neither I smoke nor do I allow anybody in the family to smoke in my home. The rest, be happy, stay positive, and help others, this can make a lot of difference in your health too. Helping others is actually good for your overall health. Your generosity will not only bring about a change in others life but I believe that it produces some special hormone in your body which gives you a lot of satisfaction, improves your mental wellbeing and make you strong in life.

Dr. Anoop Misra is the Chairman of Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology. He is also the Chairman of National Diabetes, Obesity and Cholesterol Foundation (N-DOC), and Vice President of Diabetes Foundation (India) (DFI).

Things you do to maintain your work-life balance: I maintain a strict discipline so as to compartmentalize time for work and then personal life and do regular exercise to enable augmentation of clear thinking and generate ideas. Another thing that I do to keep a balance between my work and family life is planning my day ahead. Much of my days planning is done while listening to music or exercising outdoors. Also, I always try to think of ways to increase the efficiency of the workforce, so as to achieve daily objectives in a shorter time and save time for home. Everybody should have some me time to relax, it allows your mind and body to repair. For me relaxation time in the evening is sacrosanct; I avoid phone calls during this time.

Things you do to keep your blood sugar levels under control: There are simple things that I do keep sugar and blood pressure under control, and keep my heart ticking regularly. In short, to keep myself fit. There is no magic mantra in following these rules. And I would like all people to follow the same to avoid diabetes, hypertension or heart disease; and those who are patients, to manage the conditions effectively.

Dr. Nikhil Modi is a well-known Pulmonologist with experience of more than 13 years. Presently he is working as a Consultant in the Department of Respiratory, Critical care, and Sleep medicine at Indraprastha Apollo Hospital, New Delhi.

Things you do to maintain your work-life balance: First and foremost work comes first in any situation and so I make sure that I am available whenever my patients need me. At the same time, your family is also important and so I try to spend as much quality time as possible with them, whenever I dont have any emergency case. Also, those times spend with your family also act as a stress buster. Thats why it important to give equal importance to work and life. But in this situation, our patients need me more than my family and I am committed to my work.

Things you to keep your lungs healthy: When it comes to keeping myself fit and my lungs healthy, it starts from early morning with exercises like yoga or walking, followed by a healthy and heavy breakfast. Since doctors are quite busy these days, I dont get much time for exercise but whenever I get time, I do some sort of exercise. When youre going in a place where you have to see patients who are infected with COVID-19, you have to be strong from inside too. Frequent small meals also help provide the nutrients your body needs to keep the immune system strong. The most important thing to keep your lungs healthy is to stay away from smoking and pollution. If you can do yoga and deep breathing for at least 10 minutes daily, its the best you can do to your lungs.

Dr. Pulin Kumar Gupta is currently associated as Professor (Medicine), Ram Manohar Lohia Hospital, Delhi.

Things you do to maintain your work-life balance: These days due to the COVID-19 pandemic, theres no fixed timing for our work. I leave for the hospital at 8 and but then you dont know when our work will end. If I am able to reach home early like 7 in the evening, I always spend some time with my kids, have dinner with them, or play an indoor game. Thats how I try to maintain my work-life balance. Since I am on COVID-19 duty these days, I also take all the necessary precautions like keeping my shoes outside, changing my clothes immediately after reaching home, and taking a bath. For the safety of my family, I stay in a separate room and avoid doing certain things that I used to do before the pandemic like kissing my kids.

Things you to keep yourself healthy: A healthy diet is a must to stay healthy and its more important now. My diet includes lots of protein, like boiled eggs, paneer, and soybean. I also eat 30 gm of almond and lots of fruit. There is very little fat in my diet. I drink turmeric milk twice daily in the morning and at night to boost my immunity. I also make sure that I drink plenty of water and limit alcohol intake. In the evening I walk on my treadmill for about 45 minutes daily. In the hospital, during lunchtime I play table tennis with my colleagues. Thats how I try my best to keep myself healthy during this pandemic.

Published : July 1, 2020 10:48 am | Updated:July 1, 2020 11:12 am

See the original post:
Doctors Day 2020: Four pandemic heroes share how they maintain their work-life balance and keep themselves h - TheHealthSite

Recommendation and review posted by Bethany Smith

Scary Mommy and Westend61/Getty

So, 2020 has really been a shit year.

It has been for nearly everyone, of course, and when the stuff stops hitting the fan, we all need to take a collective breath, pat ourselves on the back, and celebrate.

I had a busy year planned for 2020: Im a gynecologic surgeon seeing patients and trying to build a badly needed menopause clinic in a local hospital here in Seattle. Im editing a book, and consulting and providing telemedicine care for women in menopause as Chief Medical Officer at Gennev.

But then in January, I got a diagnosis of breast cancer, and suddenly I was making new plans. Somehow I had to carve out five weeks from this life to recover from a double mastectomy, then more time later for recovery from reconstruction. I managed it, barely, to have my first surgery in March.

I thought I had it pretty much under control. My patients were scheduled with other physicians, meetings were on hold, a bunch of work up-front meant I could relax and heal. In February, I went on a vacation to Mexico, where I spent a lot of time crying on beaches and into margaritas with friends. It helped. I came back ready to move forward.

And then COVID-19 hit, and it hit right here at home: epicenter, Seattle.

Suddenly the chaos and noise of my own life have expanded to a global level, and all of us in health care are scrambling to find answers, help others stay calm and safe, keep ourselves as safe as possible on the front lines, and meanwhile Im trying desperately to ignore the little voice inside thats saying, What about me?

As a physician and surgeon, I know what cancer looks like. I have an idea how it progresses and how bad treatment can be. I wanted to get on with it, have the surgery and whatever treatment so I could recover and get back to my life. But with my first surgery scheduled for mid-March, now it looked like those carefully extracted five weeks werent mine anymore.

Oh, and did I mention, suddenly my kids were home all the time? Theyre pretty much grown, so I have it easier than many, but the advanced clusterf*ck of trying to home school an attention-deficit high schooler while sympathizing with my college kid who was missing out on some pretty important stuff in her education and future career (shes a dancer) deflated any zen I managed to scrape together in a hurry.

This is a tough time for teens and young adults who rely on their social structures more than ever, and suddenly mine were stuck with a sick mom and Zoom.

Despite being a pretty practical person, I havent always approached my health practically. It wasnt until I was diagnosed as pre-diabetic at 42 that I finally started taking some things seriously. Perimenopause had added some belly fat and bumped up my bad cholesterol, so I at last started exercising regularly and taking medication, since eating better wasnt enough anymore.

However, as someone with a family history of cancers, Im a huge advocate of screening and started annual mammograms at 40.

Now thats irony, Alanis.

As with most women in their 40s, the mammograms showed that I had dense breasts, but nothing particularly concerning.

Then Gennev started working with MiraKind, an organization researching the connection between a gene defect called the KRAS variant and a greater likelihood of developing certain cancers. I got tested, and sure enough, I was a carrier. Knowing being KRAS positive could mean I was more susceptible to breast cancer, I added an MRI to my usual mammogram (remember, dense breasts).

Two days later, they called me and said, So, there are a couple of masses on your MRI. A couple of biopsies revealed invasive ductal carcinoma. More testing, more biopsies, more black and blue boobs.

Now I had a decision to make: I could get bilateral lumpectomies and sign up for a life of going in every six months and probably having to get biopsies every six months. Eventually theyd find something, and Id be right back here again. Im a doctor I knew how Id feel with these things on my chest, knowing there was cancer in them. So I decided on a bilateral mastectomy.

In the end, it was the right choice: there was more cancer that hadnt yet been detected. It was small, sure; but it wouldnt always be small.

The hospital where I would have my surgery started disallowing non-essential surgery the week before my mastectomy was planned. And surgery on anyone who was medically fragile old, ill, likely to respond poorly to anesthesia, etc. was postponed.

I wanted nothing to do with postponing the surgery. I had done everything to make taking those five weeks okay for everyone it affected patients, family, colleagues. Just the thought of redoing all that was exhausting. I had taken the time to take care of me, and dammit, I was going to take care of me!

In the end, it came down to the fact that I was young and healthy going in, so I wouldnt need an ICU bed that was needed for a COVID-19 patient. Id be out the next day. So we went ahead.

On March 19, all my breast tissue was removed.

March and April were spent alternating holding my breath and breathing sighs of relief: biopsy of sentinal nodes revealed no signs of spreading. Testing of the tumor showed it wasnt aggressive enough to require chemotherapy. Because I did what I did when I did it, the cancer was Stage 1. Ill be treated with hormone therapy; Im on Tamoxifen. They got great margins when they did the surgery, and I dont need radiation.

Ask anyone who knows me: Im pretty blunt. Im never unkind, but if a patient wants a lot of touchy-feely handholding, they should probably find another doctor. However. Telling your daughters you have breast cancer is not an occasion for blunt.

Not only was I telling them I was sick, I also knew they would watch me for signs of what was to come for them. Realistic but reassuring is a delicate dance. Fortunately, I was able to be pretty reassuring. It was Stage 1, not a particularly aggressive form, and Id be fine on the other side. But I also wanted to be honest with them about their own health and the screenings theyd need, given their family history.

I could complain about how unfair it is to have bad genetics, or how much it sucks to take care of myself and still have cancer, but I really have a shit happens approach to life, and it served me well. Yelling about how unfair it is as much as I was screaming it on the inside sometimes wasnt going to help me or my kids get through it.

COVID and being isolated together certainly didnt make it easier. This is a hard time for kids their lives are dominated by social things, the groups theyre in, who they communicate with, the things they do. Theyre missing out on things. So managing their emotions and my own is really tough; Im maybe not as patient as I would be otherwise, because Im going through some shit. I have cancer and it sucks. I dont tell them everything because it wouldnt help them. But I try to be open and honest because I know your imagination can sometimes be worse than the truth.

It could be easy to let cancer and COVID take charge and send me screaming to a safe room, but thats really not my style. I take precautions to protect myself from the coronavirus, but Im still seeing patients. I know that as a healthcare professional, Ill get it eventually. I just intend to be at full strength when it happens.

I walk every day, three to five miles with my dog. I run three days a week. Im back in physical therapy because too many hours performing surgery have caused problems with my neck. I truly think staying active has helped with my recovery.

Recovery was tough, not so much because of pain, but because COVID meant my friends and family couldnt help the way they wanted to: they couldnt come clean my house or cook meals, though many dropped meals on my doorstep, rang the bell and ran.

I have two sisters who live locally, and it was killing them not to be able to come and help. One sis is a chef and she just wanted to come and cook for me, but she couldnt come into my house. That was hard, but honestly, it was harder for them than me, since I was pretty out of it for the first two weeks after surgery.

So, yeah, 2020 is a shit year, but at least some things will get easier now. No more mammograms for me, because the reconstruction surgery scheduled for July will be done using my own abdominal tissue. From now on, a check up involves making sure the area around the reconstruction is healthy and cancer-free, including the lymph nodes and chest wall.

I know a lot about health, particularly womens health, because its my job. And I made a lot of decisions, together with my doctors, based on the knowledge I have. I wanted to share a few things that might help others have an easier time of it, COVID or no.

It might not prevent you from having health problems, but being fit can make it easier to handle the treatment and make recovery easier and faster.

Diabetes, cancer, heart disease are all in my family history. Knowing that helped me make better choices. And the KRAS test prompted me to do the MRI that revealed the cancer while it was still early-stage. Knowledge matters.

When I got that pre-diabetes diagnosis, I decided it was time to get a handle on me Ive spent my life caring for others as a doctor, wife, and mom. I was trained in residency to go until you drop. But suddenly I realized I needed to focus on my own health too. I made changes in work and home life, ate better, took meds. I wanted to feel good and I did. And when this came up, I had good endurance, strong muscles, a strong cardiovascular system, even strong legs and abs to help me get out of bed when I couldnt use my arms!

For the past few years, I had managed my sleep patterns to feel better, and through all of this, I managed to for the most part still get good sleep.

Because I made great decisions for a solid few years before this diagnosis, there was a little WTF? that I did everything right and still got this disease. But we live in a toxic world, I hadnt always made great decisions, my work has at times been really stressful, plus, I just had some bad dumb luck. Theres always been that bit of pessimism in me because my family history indicates that I have at least one cancer in my future. But, I thought, this can be dealt with, Im healthy going in, and Ill take this one day at a time.

Ive lost sensation in my chest area. I bump into things, and I dont even know it. Its weird, and Im mourning the loss of sensation there, but I knew it would happen, and I was at least somewhat prepared. Make plans. Have a wedge for your bed. Know what the drain looks like coming out of your body. Know who will help you shower and who will make you laugh when your life just has so much yuck in it. Because theres a lot of yuck; youre going to need your sense of humor. And if yours is AWOL, borrow some from a friend.

Just because I knew what was coming doesnt mean I didnt have emotions around it. I had to let myself grieve the loss of my breasts even as I was taking control of the decision to have the bilateral mastectomy. I had to stop being practical and allow myself to mourn.

Living in Seattle, I am blessed with having so many amazing medical professionals in cancer treatment. But I also wanted to work with someone I was comfortable with, someone I trusted with my body, with my future. I needed to feel they were making decisions that worked for me. Please know that youre not hurting a doctors feelings if you decide to move on from them because youre not connecting well with them. It happens all the time, and docs understand how important it is that you feel comfortable. I picked people I felt great with and felt we were making decisions for the same reasons.

Hey, I get a tummy tuck out of this get lemons, make lemonade! Im not exactly going to be voluptuous, but Im good with Bs or even really big As that look nice.

Dont rely on self-breast exams even when I knew where my biggest tumor was, I couldnt feel it. Also, some people are pushing thermograms, claiming theyre safer than mammograms, but they are NOT safer, so do your research before committing. A mammogram isnt perfect, but its a good tool and has saved lives. And you wont get breast cancer from mammograms. The radiation is minimal: you get more from walking around for two weeks in the world. Be informed about your choices before you make them.

I could have put off the reconstruction until next year, when theres a chance COVID-19 will be behind us, and things will be back to whatever normal there is on the other side. But I figured, 2020 is already a hot mess of a year, I might as well shove all the shit into this one and look forward to 2021.

So thats what Im doing. May you get all your shit behind you too. Now go schedule your next screening.

Go here to see the original:
Im A Physician Who Had Breast Cancer, And Here Are The Knowledge-Based Decisions I Made For Myself - Scary Mommy

Recommendation and review posted by Bethany Smith

Folch M, Pigem I, Konje JC. Mllerian agenesis: etiology, diagnosis, and management. Obstet Gynecol Surv. 2000;55:6449.

CAS PubMed Google Scholar

Brucker SY, Oppelt P, Ludwig KS, Wallwiener D, Beckmann MW. Vaginale und uterine Fehlbildungen Teil 2 Geburtshilfe Frauenheilkd. 2005; 66 (11): R221-R224.

Londra L, Chuong FS, Kolp L. Mayer-Rokitansky-Kuster-Hauser syndrome: a review. Int J Womens Health. 2015;7:86570.

PubMed PubMed Central Google Scholar

Morcel K, Guerrier D, Watrin T, Pellerin I, Levque J. The Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome: clinical description and genetics [article in French]. J Gynecol Obstet Biol Reprod (Paris). 2008;37:53946.

CAS Google Scholar

Carranza-Lira S, Forbin K, Martinez-Chquer JC. Rokitansky syndrome and MURCS association--clinical features and basis for diagnosis. Int J Fertil Womens Med. 1999;44(5):2505.

CAS PubMed Google Scholar

Morcel K, Dallapiccola B, Pasquier L, Watrin T, Bernardini L, Guerrier D. Mayer-Rokitansky-Kster-Hauser syndrome. Eur J Hum Genet. 2012;20(2):13.

Google Scholar

Lermann J, Mueller A, Wiesinger E, Hberle L, Brucker S, Wallwiener D, Dittrich R, Renner SP, Beckmann MW, Oppelt PG. Comparison of different diagnostic procedures for the staging of malformations associated with Mayer-Rokitansky-Kster-Hauser syndrome. Fertil Steril. 2011;96(1):1569.

PubMed Google Scholar

Patnaik SS, Brazile B, Dandolu V, Ryan PL, Liao J. Mayer-Rokitansky-Kster-Hauser (MRKH) syndrome: a historical perspective. Gene. 2015;555(1):3340.

CAS PubMed Google Scholar

Pai A, Shakir M. Mayer-Rokitansky-Kuster-Hauser syndrome type II: A rare case. Indian J Hum Genet. 2013 Jan;19(1):1135.

PubMed PubMed Central Google Scholar

Nakum A, Kumawat K, Chauhan H, Parikh JV. Mayer-Rokitansky-Kuster-Hauser (MRKH) Syndrome Type 2: Atypical Presentation of Rare Case. Natl J Med Res. 2013;3(4):40911.

Google Scholar

Dragusin R, Tudorache , Surlin V, Lichiardopol C, Iliescu DG. Importance of Laparoscopic Assessment of the Uterine Adnexa in a Mayer-Rokitansky-Kuster-Hauser Syndrome Type II Case. Curr Health Sci J. 2014;40(2):1447.

PubMed PubMed Central Google Scholar

Raybaud C, Richard O, Arzim M, David M. Mayer-Rokitansky-Kster-Hauser syndrome: associated pathologies. Arch Pediatr. 2001;8:120913.

CAS PubMed Google Scholar

Braun-Quentin C, Billes C, Bowing B, Kotzot D. MURCS association: case report and review. J Med Genet. 1996;33:61820.

CAS PubMed PubMed Central Google Scholar

Oppelt P, Renner SP, Kellermann A, et al. Clinical aspects of Mayer-Rokitansky-Kuester-Hauser syndrome: recommendations for clinical diagnosis and staging. Humanit Rep. 2006;21:792.

Google Scholar

Hofstetter G, Concin N, Marth C, Rinne T, Erdel M, Janecke A. Genetic analyses in a variant of Mayer-Rokitansky-Kuster-Hauser syndrome (MURCS association). Wien Klein Wochenschr. 2008;120(13-14):4359.

CAS Google Scholar

Rall KK, Eisenbeis S, Henninger V, Henes M, Wallwiener D, Bonin M, Brucker S. Typical and Atypical Associated Findings in a Group of 346 Patients with Mayer-Rokitansky-Kuester-Hauser Syndrome. J Pediatr Adolesc Gynecol. 2015;28(5):362836.

PubMed Google Scholar

Bungartz J. Das MRKH-Syndrom: Klinik, Analyse der Fehldiagnosen und Entwicklung eines Leitfadens zur Differenzialdiagnostik und zur Vermeidung von Malpractice. Medizinische Fakultt Tbingen 2012; Dissertation.

Wottgen M, Brucker S, Renner SP, Strissel PL, Strick R, Kellermann A, Wallwiener D, Beckmann MW, Oppelt P. Higher incidence of linked malformations in siblings of Mayer-Rokitansky-Kster-Hauser syndrome patients. Hum Reprod. 2008;23(5):122631.

CAS PubMed Google Scholar

Ledig S, Schippert C, Strick R, Beckmann MW, Oppelt PG, Wieacker P. Recurrent aberrations identified by array-CGH in patients with Mayer-Rokitansky-Kster-Hauser syndrome. Fertil Steril. 2011;95(5):158994.

CAS PubMed Google Scholar

Rall KK, Eisenbeis S, Barresi G, Rckner D, Walter M, Poths S, Wallwiener D, Riess O, Bonin M, Brucker S. Mayer-Rokitansky-Kster-Hauser syndrome discordance in monozygotic twins: matrix metalloproteinase 14, low-density lipoprotein receptor-related protein 10, extracellular matrix, and neoangiogenesis genes identified as candidate genes in a tissue-specific mosaicism. Fertil Steril. 2015;103(2):494502.

CAS PubMed Google Scholar

Guerrier D, Mouchel T, Pasquier L, Pellerin I. The Mayer-Rokitansky-Kster-Hauser syndrome (congenital absence of uterus and vagina)--phenotypic manifestations and genetic approaches. J Negat Results Biomed. 2006;5:1. https://doi.org/10.1186/1477-5751-5-1 .

Hohl MK. Modernes Management der angeborenen (Mayer-Rokitansky-Kster-Hauser-Syndrom, MRKH) und erworbenen Vaginalaplasie. Frauenheilkunde aktuell. 2007;1:412.

Google Scholar

Rall KK, Brucker S. Die drei A der Vaginalaplasie kein differentialdiagnostisches Chamleon. Frauenarzt. 2007;48(10):9408.

Google Scholar

Aittomaki K, Eroila H, Kajanoja P. A population-based study of the incidence of mullerian aplasia in Finland. Fertil Steril. 2001;76(3):6245.

CAS PubMed Google Scholar

Master-Hunter T, Heiman TL. Amenorrhea: Evaluation and Treatment. Am Fam Phys. 2006;73(8):137482.

Google Scholar

Heller-Boersma JG, Schmidt UH, Edmonds DK. Psychological distress in women with uterovaginal agenesis (Mayer-Rokitansky-Kster-Hauser syndrome, MRKH). Psychosomatics. 2009;50:27781.

PubMed Google Scholar

Bean EJ, Mazur T, Robinson AD. Mayer-Rokitansky-Kster-Hauser syndrome: sexuality, psychological effects and quality of life. J Pediatr Adolesc Gynecol. 2009;22:33946.

CAS PubMed Google Scholar

Krupp K, Fliegner M, Brunner F, Brucker SY, Rall KK, Richter-Appelt H. Quality of Life and Psychological Distress in Women with Mayer-Rokitansky-Kster-Hauser Syndrome and Individuals with Complete Androgen Insensitivity Syndrome. Open J Med Psychol. 2014;3:21221.

Google Scholar

Schffeler N, Brucker SY, Rall KK, Zipfel S. Psychological strains in patients with MRKHS and psychosomatic support. Conference Paper. J Psychosom Obstetr Gynecol. 2010;31:46.

Google Scholar

Kimberley N, Hutson JM, Southwell BR, Grover SR. Well-being and sexual function outcomes in women with vaginalagenesis. Fertil Steril. 2011;95(1):23841.

PubMed Google Scholar

ACOG Committee Opinion. Vaginal agenesis: Diagnosis, Management and Routine Care. Obstet Gynecol. 2006;108(6):16059.

Google Scholar

Rall KK, Schickner MC, Barresi G, Schnfisch B, Wallwiener M, Wallwiener CW, Wallwiener D, Brucker SY. Laparoscopically assisted neovaginoplasty in vaginal agenesis: a long-term outcome study in 240 patients. J Pediatr Adolesc Gynecol. 2014;27(6):37985.

PubMed Google Scholar

Brucker SY, Gegusch M, Zubke W, Rall K, Gauwerky JF, Wallwiener D. Neovagina creation in vaginal agenesis: development of a new laparoscopic Vecchietti-based procedure and optimized instruments in a prospective comparative interventional study in 101 patients. Fertil Steril. 2008;90(5):194052.

PubMed Google Scholar

Brucker SY, Rall K, Campo R, Oppelt P, Isaacson K. Treatment of congenial malformations. Semin Reprod Med. 2011;29(2):10112.

PubMed Google Scholar

Nippert I. Frauengesundheitsforschung und gender based medicine. In: Cottmann A, Kotendieck B, Schildmann U, editors. Das undisziplinierte Geschlecht. Frauen und Geschlechterforschung Einblick und Ausblick. Wiesbaden: VS Verlag; 2000. p. 5167.

Google Scholar

Regitz-Zagrosek V. Sex and gender differences in health. Science & society series on sex and science. EMBO Reports. 2012;13:596603.

CAS PubMed PubMed Central Google Scholar

Pfaff H. Versorgungsforschung Begriffsbestimmung, Gegenstand und Aufgaben. In: Pfaff H, et al., editors. Gesundheitsversorgung und Disease Management Grundlagen und Anwendungen der Versorgungsforschung. Bern: Hans Huber Verlag; 2003. p. 1323.

Google Scholar

Crowley R, Wolfe I, Lock K, McKee M. Improving the transition between paediatric and adult healthcare: a systematic review. Arch Dis Childhood. 2011;96(6):54853.

CAS Google Scholar

Lugasi T, Achille M, Stevenson M. Patients perspective on factors that facilitate transition from child-centered to adult-centered health care: a theory integrated metasummary of quantitative and qualitative studies. J Adolesc Health. 2011;48(5):42940.

PubMed Google Scholar

Rall KK, Wallwiener M, Rieen I, Zipfel S, Wallwiener D, Brucker S. Optimierung von Aufklrung, Betreuung und Compliance bei Patientinnen mit seltenem gynkologischen Krankheitsbildam Beispiel des Mayer-Rokitansky-Kster-Hauser-Syndroms (MRKH-Syndrom). Geburtsh Frauenheilk. 2008;68:11025.

Google Scholar

Grber-Grtz D, Kronenthaler A, Rieger MA, Rall KK, Schffeler N, Hiltner H, Ueding E, Brucker SY, Simoes E. Entwicklung eines Versorgungsmodells zur Verbesserung der Transitionsversorgung bei Seltenen Erkrankungen am Beispiel MRKH Ergebnisse einer systematischen Literaturrecherche. Meeting Abstract 12. Deutscher Kongress fr Versorgungsforschung. Berlin, 23.-25.10.2013. Dsseldorf: German Medical Science GMS Publishing House; 2013. DocPO4-1-06-213. doi: https://doi.org/10.3205/13dkvf264 .

Wagner A, Brucker SY, Ueding E, Grber-Grtz D, Simoes E, Rall K, Kronenthaler A, Schffeler N, Rieger MA. Treatment management during the adolescent transition period of girls and young women with Mayer-Rokitansky-Kster-Hauser syndrome (MRKHS): a systematic literature review. Orphanet J Rare Dis. 2016;11(1):152 Review.

PubMed PubMed Central Google Scholar

Simoes E, Kronenthaler A, Schffeler N, Wagner A, Rall KK, Sokolov AN; Hiltner H, Ueding E, Emrich C, Psch LS, Baur MC, Gerlach F, Mohr S, Krebs E, Eissler M, Zipfel S, Rieger MA, Wallwiener D, Brucker SY. Entwicklung eines Versorgungsmodells zur Verbesserung der Transitionsversorgung bei Seltenen Erkrankungen am Beispiel weiblicher Jugendlicher mit genitaler Fehlbildung. TransCare O Schlussbericht. Tbingen 2016. URL: http://edok01.tib.uni-hannover.de/edoks/e01fb16/865968330.pdf (Zugriff: 01.03.2017).

Simoes E, Kronenthaler A, Emrich C, Rieger MA, Rall KK, Schffeler N, Hiltner H, Ueding E, Brucker SY. Development of a provisional model to improve transitional care for female adolescents with a rare genital malformation as an example for orphan diseases. Biomed Res Int. 2014;913842. https://doi.org/10.1155/2014/913842 .

Pittock ST, Babovic-Vuksanovic D, Lteif A. MayerRokitanskyKsterHauser anomaly and its associated malformations. Am J Med Genet Part A. 2005;135(3):3146.

PubMed Google Scholar

Nationales Aktionsbndnis fr Menschen mit Seltenen Erkrankungen (NAKSE). Nationaler Aktionsplan fr Menschen mit Seltenen Erkrankungen. Handlungsfelder, Empfehlungen und Manahmenvorschlge. Bonn 2013. URL: http://www.bmg.bund.de/fileadmin/dateien/Downloads/N/NAMSE/Nationaler_Aktionsplan_fuer_Menschen_mit_Seltenen_Erkrankungen_-_Handlungsfelder__Empfehlungen_und_Massnahmenvorschlaege.pdf (Zugriff: 02.08.2016).

Bodemann G. Welche Bedeutung haben Partnerschaft und Liebe fr Jugendliche heute? Eine deskriptive Untersuchung. Zeitschrift fr Familienforschung. 2003;15(3):91104.

Google Scholar

Statistisches Bundesamt (Hrsg.). Datenreport 2006. Zahlen und Fakten ber die Bundesrepublik Deutschland. Bonn 2006 (Bundeszentrale fr politische Bildung, Bd. 544).

Delaineb M, Ohl J. Activit sexuelle et qualit de vie chez les patientes atteintes dun syndrome de Mayer-Rokitansky-Kuster-Hauser. Gyncol Obsttr Fertil. 2014;42(12):86571.

Google Scholar

Statistisches Bundesamt. Bildungsstand der Bevlkerung. Wiesbaden 2015.

Shankar NL, Park CL. Effects of stress on students' physical and mental health and academic success. Int J School Educ Psychol. 2016;4(1):59.

Google Scholar

Simoes E, Sokolov AN, Kronenthaler A, Hiltner H, Schaeffeler N, Rall K, Ueding E, Rieger MA, Wagner A, Poesch LS, Baur M-C, Kittel J, Brucker SY. Information ranks highest: Expectations of female adolescents with a rare genital malformation towards health care services. PLoS ONE. 2017;12(4):e0174031.

PubMed PubMed Central Google Scholar

Simoes E, Sokolov AN, Graf J, Pavlova MA, Brucker SY, Wallwiener D, Schmahl FW, Bamberg M. Klinische Sozialmedizin -Warum? Von der epidemiologischen Assoziation zur personalisierten Sozialmedizin am Beispiel der Versorgung bei Mammakarzinom [Why Strive after Clinical Social Medicine? From Epidemiological Association to Personalized Social Medicine: a Case of Breast Cancer Care]. Gesundheitswesen. 2016;78(2):97-102.

Nahum GG. Uterine anomalies: How common are they, and what is their distribution among subtypes? J Reprod Med. 1998;43:87787.

CAS PubMed Google Scholar

Oppelt P, von Have M, Paulsen M, Strissel PL, Strick R, Brucker SY, Wallwiener D, Beckmann MW. Female genital malformations and their associated abnormalities. Fertil Steril. 2007;87(2):33542.

PubMed Google Scholar

Link:
Rare genital malformations in women's health research: sociodemographic, regional, and disease-related characteristics of patients with...

Recommendation and review posted by Bethany Smith

New York: Clinicians can examine COVID-19 patients' blood to identify those at greatest risk of severe illness and to pinpoint those most likely to need a ventilator, according to a new study.

The discovery could lead to new treatments to prevent deadly "cytokine storms" seen in severe cases of COVID-19. It also may help explain why diabetes contributes to worse outcomes in patients with the coronavirus.

The researchers from the University of Virginias (UVA) found that the levels of a particular cytokine in the blood upon diagnosis could be used to predict later outcomes.

Cytokines - proteins produced by immune cells - are responsible for severe overreactions by the immune system, known as cytokine storms, associated with COVID-19 and other serious illnesses.

"The immune response that we discovered to predict severe shortness of breath in COVID-19 is known in other pulmonary diseases to cause damage," said study researcher Bill Petri from the UVA.

"So this could lead to a novel way to prevent respiratory failure in individuals infected with the new coronavirus, by inhibiting this immune cytokine. We plan to test this in a model of COVID-19 prior to considering a clinical trial," Petri added.

For the findings, the research team identified 57 COVID-19 patients treated at UVA who ultimately required a ventilator. They then tested blood samples taken from the patients within 48 hours of diagnosis or hospital admission.

The research team compared the results with those from patients who did not wind up needing a ventilator. Cytokine storms, in which the immune system spirals out of control, are typically associated with an established group of cytokines.

But the best predictor of COVID-19 outcomes was an "underappreciated" cytokine more associated with allergies, the researchers reported. High levels of that cytokine, IL-13, were associated with worsened Covid-19 outcomes regardless of patients' gender, age or other health problems.

The researchers also identified two more cytokines associated with severe outcomes, though the duo had less ability to predict the need for a ventilator.

In addition, the researchers found that levels of two other cytokines were significantly higher in patients with elevated blood sugar. This "pro-inflammatory response," they said, may help explain why diabetes is associated with worse COVID-19 outcomes. In short, the body is primed to respond too strongly to the infection.

The researchers said the discovery could become part of a scoring system to let doctors flag at-risk COVID-19 patients for closer monitoring and personalized interventions. The finding also identifies cytokines doctors could target as a new treatment approach.

Read this article:
Blood test can predict the severity of COVID-19: Study - Free Press Journal

Recommendation and review posted by Bethany Smith

There are countless dieting tips, tricks, recipes, and meal plans you can find in a single Google search, all promoting different ways to lose weight. But what you eatand how muchis affected by more than just your hunger, desire to control eating, or diet plan.

The first thing to understand when you want to lose a few pounds is something experts call your set-point weight: This is your body's "happy weight"it's a size that your brain and body try to maintain, and it includes the fat stores on your belly and elsewhere.

According to registered dietitian Dara Dirhan, this amount of fat becomes what the brain has determined to be the best for optimal function.

Two hunger hormones are responsible for trying to regulate your body's set point: ghrelin and leptin, says Dirhan. Ghrelin is known as the "hunger hormone" because it is secreted when the brain senses that available energy stores are running low.

UP NEXT

This hormone generates feelings of hunger that convince you it's time to get some food in your belly. Your digestive system converts the calories to blood sugar (glucose), which can then power muscles, organs, the brain, and other cellular functions.

Leptin is known as the "satiety hormone"it's released when your body senses that you've eaten enough; it signals the brain that energy levels have been met.

These signals have three primary functions, according to David Prologo, MD, a dual board-certified obesity-medicine physician, and interventional radiologist. They tell your body when to seek food, when to slow down and conserve energy, and when to store and preserve fuel if it senses deprivation (a leftover from the days when famines weren't uncommon)and this is all in the name of survival.

The brain isn't concerned with how you look, Dr. Prolongo says. "It is concerned with maintaining life." Your body and brain are programmed to remain stable at your set point.

How your brain changes on a diet

When you first start a new dietor you aren't consuming enough energy for your brain's needsyou can experience symptoms like weakness, hunger, depression, fatigue, and headaches, among other symptoms. The good news is that after several weeks the brain eases up on these signals, Dr. Prologo says, as your body begins to find a new set point.

Jason McKeown, MD, neurologist and CEO of Modius Health, adds that once your body reaches a new set point, you'll see a reduction in your appetite and cravings. "To maintain results, diets in the long-term can influence this set-range, making your brain adapt and be comfortable at a lower weight," Dr. McKeown says. It's also possible to drive your set point upwards, he warns.

Changing your set point is no easy task: It can take months and sometimes even years, says Dr. McKeown, which is why you should set long-term diet and weight goals. "In the long run you could reset the weight range that your brain has established which will cause your body to speed up metabolism and decrease appetite, becoming comfortable with a lower weight," Dr. McKeown says. "Whereas in the short run, you may lose a few pounds, but youll often plateau and see the weight creep back up as its not enough to influence the weight your brain and body is happy with."

Food quality makes a difference

The quality of your diet is another variable. For brain health and well-being, Dirham recommends choosing a whole foods diet as much as possible. This means staying away from foods that have been processed or refinedenergy-dense, high-calorie foodsand incorporating healthier whole foods like fresh fruits and vegetables, lean meat, poultry, fish, and whole grains, Dirhan says.

Instead of focusing on what she calls a "calorie salary," stick to a whole food diet and practice mindful eating (slowing down your eating and taking time to appreciate meals). "This will make sure the brain is happy while aiding in weight loss," she says. (Focusing on calories is just one of many things keeping you from losing weight.)

Farrah Hauke, a psychologist in Scottsdale, Arizona who specializes in weight management and weight loss, believes that people are more likely to binge when they overly restricting what they eat. When people eat foods higher in fat or sugar, the brain releases "feel-good" chemicals that make the indulgence more rewarding. "We don't see this same brain stimulation with foods such as broccoli and grilled chicken breast," Hauke says.

When you diet, you can lose out on those feel-good chemicals, which means you're less likely to get those brain-boosting rewards from dieting. Hauke recommends you find other ways to reward yourself and feel satisfied; the goal is to avoid what she calls "cognitive distortions"negative thinking patterns that contribute to the common all-or-nothing diet approach.

The experts all agree that rigid rules, unrealistic expectations about eating, and fad diets aren't the best strategies for your body and brain. Instead, focus on the quality of your diet, listening to your body's hunger cues, and adding in physical activity. This, along with these tiny changes, can help you lose weight.

Gallery: 101 Ultimate Weight Loss Tips for Summer 2020 (Best Life)

Originally posted here:
This Is What Happens to Your Brain on a Diet - MSN Money

Recommendation and review posted by Bethany Smith

A 19-month-old boy with a medical history of 1 febrile seizure presented to the emergency department (ED) with 2 days of vomiting and 1 day of diarrhea. He was accompanied by his nonEnglish-speaking mother, who reported several episodes of nonbloody, nonbilious emesis and dark brown, watery stools. The patient had decreased intake of solid foods, but he had been breastfeeding well. Because of his diarrhea, the patients mother was unsure how many voids he had had in the past day. He had not had fevers. The family history was significant for the patients father recently being diagnosed with hepatitis C. The patients mother brought him into the ED because of his symptoms and concern that he looked yellow.

In the ED, the patient was afebrile with normal vital signs for his age (including heart rate of 146 beats per minute), and he was well appearing and active with moist mucous membranes and a capillary refill of <2 seconds. However, the ED provider additionally documented that the patient appeared moderately dehydrated [and] slightly jaundiced, and he ordered a comprehensive metabolic panel (CMP). All values were within normal limits, including total bilirubin, except for a low bicarbonate of 16 mmol/L (normal 2130 mmol/L) and an elevated alkaline phosphatase (ALP) of 926 U/L (normal 129291 U/L). The provider consulted endocrinology for the elevated ALP, who noted a broad differential for elevated ALP and that transient hyperphosphatasemia is a diagnosis of exclusion. They recommended checking 25-hydroxyvitamin D, phosphate, and parathyroid hormone to

Original post:
An Explosive Workup for Diarrhea: The Cascade Effect From an Incidental Finding on a Laboratory Panel - AAP News

Recommendation and review posted by Bethany Smith